Drug ineffectiveness; Drug toxicity; Psychotropic drugs; Rwandan patients
Abstract :
[en] OBJECTIVES:
In Rwanda, no therapeutic monitoring of psychotropic drugs is done. This results in difficult treatment optimisation and exposition to a high risk of toxicity and drug ineffectiveness for patients under treatment. This study aimed to determine blood concentration levels of psychotropic drugs in Rwandan patients and identify problems associated with the lack of therapeutic drug monitoring (TDM) of these drugs.
METHODS:
The analysis was performed on 1 ml of serum sample using prazepam as internal standard. Regarding the step of sample preparation, we used a liquid-liquid extraction with a mixture of organic solvents: diethyl ether/dichloromethane/hexane/n-amyl alcohol (50/30/20/0.5:V/V). A Waters Alliance 2695 was used for analysis. The chromatography was run on a Symmetry C8 column and as mobile phase acetonitrile and phosphate buffer (pH 3.8) were used.
RESULTS:
Concerning the results, serum samples from 128 patients were analysed. Twenty-one different psychotropic drugs belonging to various pharmacological classes were detected and quantified. Analytical results were put into three categories based upon therapeutic reference ranges (TRR) of various drugs: subtherapeutic, therapeutic and supratherapeutic. For a total of 237 analyses, results within TRR represented 46% while 47 and 8% of results were, respectively, below and above TRR.
CONCLUSION:
It was therefore concluded that patients under psychotropic treatment in Rwanda are exposed to both the risk of drug ineffectiveness and the risk of toxicity (54%) with only 46% of results within the TRR. Consequently, TDM is needed to optimise psychotropic treatment in Rwandan patients.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Hahirwa, Innocent; National University of Rwanda > Laboratory of Analysis of Food, Drugs, Water and Toxics
DENOOZ, Raphael ; Centre Hospitalier Universitaire de Liège - CHU > Toxicologie clinique
Karangwa, Charles; National University of Rwanda > Laboratory of Analysis of Food, Drugs, Water and Toxics
Charlier, Corinne ; Université de Liège > Département de pharmacie > Chimie toxicologique
Language :
English
Title :
Determination of blood concentration levels of psychotrope medications in Rwandan patients
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
Addington D. Best practices: improving quality of care for patients with first-episode psychosis. Psychiatr Serv. 2009;60:1164-6.
Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, G, et al. Therapeutic monitoring of psychotropic drugs, an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit. 2004;26:167-70.
Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780-96.
Preskorn SH. CNS drug development: part I: the early period of CNS drugs. J Psychiatr Pract. 2010;16:334-9.
Preskorn SH. CNS drug development: part II: advances from the 1960s to the 1990s. J Psychiatr Pract. 2010;16:413-5.
Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348:2526-34.
Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27:10-17.
Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-65.
Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit. 2004;26:145-51.
Hiemke C. Therapeutic drug monitoring in neuropharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 1):21-7.
Hiemke C. Clinical utility of drug measurement and pharmacokinetics therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol. 2008;64:159-66.
Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29:319-26.
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76.
Raggi MA. Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic drugs. Curr Med Chem. 2002;9:1397-409.
Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52:23-33.
Munyendamutsa N. Plus de 20% des Rwandais sont traumatisés par le Génocide. Rwanda News Agency, 2010, April 7. Available from http://www.rnanews.com/index.php?option=com-content&view= article&id=3111:plus-de-20-des-rwandais-sont-traumatises-par-legenocide&Itemid=47.
Gaillard Y, Pépin G. Use of high performance liquid chromatography with photodiode array UV detection for creation of a 600-compound library: application to forensic toxicology. J Chromatogr A. 1996;763:149-63.
Hahirwa I, Charlier C, Denooz R, Karangwa C. Validation of analytical method for the determination in serum of psychotropic drugs commonly prescribed in Rwanda by HPLC-DAD. Acta Clin Belg. 2013;68(6):479.
Bauer LA. Applied clinical pharmacokinetics. 2nd ed. University of Washington, Schools of Pharmacy and Medicine; Seattle, 2008.
Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13:69-75.
Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Pharmacol. 2001;52:45-54.
Akerblad AC, Bengtsson F, Ekselius L, von Knorring L. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. Int Clin Psychopharmacol. 2003;18:347-54.
Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol. 2007;27:252-8.
Lingam R, Scott J. Treatment non-Adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164-72.
Charlier C, Pinto E, Ansseau M, Plomteux G. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol. 2000;15(6):453-9.
Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165:2497-503.
Pfuhlmann B, Gerlach M, Burger R, Gonska S, Unterecker S, Jabs B, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl. 2007;72:287-96.
Frackiewicz EJ, Jhee SS, Shiovitz TM, editors. Ethnicity in drug development and therapeutics. Cambridge: Cambridge University Press; 2011.
Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry. 1998;31(5):163-9.
Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit. 1996;18(4):393-6.
Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(3):98-104.
